ScentAware and OCT in MCI vs HC
Key facts
- Who runs it
- University of Wisconsin, Madison
- Where
- Madison, United StatesSee the site
- Trial code
- Status
- Terminated
- People taking part
- 20 people enrolled
- Started
- 15 Apr 2024
- Ended
- 5 Jun 2024
- Type of study
- Observational, 3 groups
- Treatments tested
- ScentAware
- UPSIT
- Record updated
- 23 April 2025
- Why it stopped
- slow enrollment
Who can take part
- Age
- 50 years to 80 years
- Sex
- Women and men
- Healthy volunteers
- Can take part
The registry criteria, word for word
Show all 16 criteriaShow less
Who can take part
- Adults who are ≥ 50 and ≤ 80 years of age
- Fluent in English
- Able to provide written consent
- Able to complete a 2.5-3-hour clinical visit, including sitting for spectral domain optical coherence tomography (SD-OCT) imaging for 30 minutes and taking cognitive and olfactory tests for 90-120 minutes
- Cognitive Ability and Family History of Alzheimer's Disease/Mild Cognitive Impairment (AD/MCI):; Cohort 1: Cognitively unimpaired, no family history of MCI or AD, and MMSE ≥ 26; Cohort 2: Cognitively unimpaired, a positive family history of MCI or AD, and MMSE ≥ 26; Cohort 3: An MMSE score > 22 and ≤ 25 and either; Clinically diagnosed MCI due to AD; A participant in a Wisconsin ADRC research registry with either clinically diagnosed MCI or self-reported MCI
- Cohorts 1 and 2: proficient in independent use of mobile smart devices
Who cannot take part
- A cataract extraction within 3 months prior to enrollment
- Current use of medications that may interfere with olfactory functions
- A history of significant ocular or nasal trauma that required medical/surgical intervention
- A history of intraocular surgery except cataract extraction
- A history of recurrent or chronic oto-pharyngeal-laryngeal (ORL) disease (such as chronic rhinitis, nasal polyposis, or sinus disease), head trauma, toxic exposures, upper respiratory infections at time of assessment
- A family history or diagnosis of other neurodegenerative diseases (e.g., multiple sclerosis, Parkinson's disease, Huntington's disease) or conditions that, in the opinion of the Investigators, may affect cognitive or olfactory functions
- Olfactory loss due to COVID (current olfactory loss and/or temporary loss that has been regained)
- Diagnosis of visually significant intraocular disease (such as late-stage age-related macular degeneration, glaucoma, or other optic nerve conditions related to brain tumor or multiple sclerosis), drug related vision loss or retinal damage
- Optic neuritis on both eyes
- Current use of hydroxychloroquine and tamoxifen, which are known to cause retinal toxicity that may confound OCT interpretation
Where in United States
- University of WisconsinMadison, United States
About the trial
What the trial wants to find out
The goal of this clinical trial is to learn whether a new smell test works as well as the standard clinical smell test, if there is a link between sense of smell and variations in the retina, and if these results could be used as a way to identify early stages of Alzheimer's disease. The main questions it aims to answer are:
Read full original descriptionShow less
* Whether the test is as effective and reliable as the standard test * Whether there is a link between the results of the smell test and the structure of the back of the eye
Participants will:
* complete a short questionnaire * have pictures of the inside of their eyes taken * perform two smell tests
The 3 groups in the trial
- Cohort 1
No cognitive impairment, and no family history of Alzheimer's disease
Treatment: ScentAware and UPSIT
- Cohort 2
No cognitive impairment, with a family history of Alzheimer's disease
Treatment: ScentAware and UPSIT
- Cohort 3
Mild cognitive impairment due to Alzheimer's disease
Treatment: ScentAware and UPSIT
Saves a reminder to your own calendar to look at this page again. Frontlight sends no messages and does not know you set it.
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- A Proof-of-concept Pilot Study to Determine the Efficacy of SensifyAware and Retinal Imaging in Differentiating Mild Cognitive Impairment (MCI) From Cognitively Unimpaired Controls (HC)
- Record updated
- 23 April 2025